Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P, Faber E, Divoka M, Rozmanova S, Friedecky D, Jarosova M, Indrak K. Rohon P, et al. Among authors: friedecky d. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):181-8. doi: 10.5507/bp.2011.059. Epub 2011 Nov 30. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013. PMID: 22660209 Free article.
From big data to better patient outcomes.
Hulsen T, Friedecký D, Renz H, Melis E, Vermeersch P, Fernandez-Calle P. Hulsen T, et al. Among authors: friedecky d. Clin Chem Lab Med. 2022 Dec 22;61(4):580-586. doi: 10.1515/cclm-2022-1096. Print 2023 Mar 28. Clin Chem Lab Med. 2022. PMID: 36539928 Free article.
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response.
Faber E, Friedecký D, Micová K, Divoká M, Katrincsáková B, Rozmanová S, Jarosová M, Indrák K, Adam T. Faber E, et al. Among authors: friedecky d. Int J Hematol. 2010 Jun;91(5):897-902. doi: 10.1007/s12185-010-0576-y. Epub 2010 May 1. Int J Hematol. 2010. PMID: 20437122
Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, Hajduch M. Bouchalova K, et al. Among authors: friedecky d. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):281-8. doi: 10.5507/bp.2010.043. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010. PMID: 21293538 Free article. Review.
A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment.
Faber E, Divoká M, Skoumalová I, Novák M, Marešová I, Mičová K, Friedecký D, Adam T, Jarošová M, Indrák K. Faber E, et al. Among authors: friedecky d. Leuk Lymphoma. 2016 Feb;57(2):370-375. doi: 10.3109/10428194.2015.1056184. Epub 2015 Jun 22. Leuk Lymphoma. 2016. PMID: 26022524
87 results